Key Takeaways
- • Vensana Capital, a medtech-focused venture capital and growth equity firm with approximately $1 billion in capital under management, added Maria Berkman, MD, as Partner and Ross (Rusty) Segan, MD, as Venture Partner, according to a Business Wire announcement dated June 4, 2025.
- • Berkman joins from Broadview Ventures, where she spent over a decade and rose to Director and Head of the MedTech practice and Managing Director of affiliated fund Longview Ventures, and has invested in nearly 20 medtech companies.
- • Segan brings more than 25 years of medtech industry experience, including prior service as Director of the Office of Product Evaluation and Quality at the FDA's Center for Devices and Radiological Health and as Chief Medical Officer at Olympus and Johnson & Johnson Medical Devices.
- • Vensana's managing partners framed the hires as part of a team-building push since the firm's 2019 launch, aimed at building the next generation of medtech companies.
Summary
Vensana Capital, a venture capital and growth equity firm focused on medical technology, announced the addition of Maria Berkman, MD, as Partner and Ross (Rusty) Segan, MD, as Venture Partner, according to a Business Wire release datelined Minneapolis and Washington.
Berkman joins Vensana after more than a decade at Broadview Ventures, a firm focused on early-stage investments in cardiovascular disease and stroke. She was most recently Director and Head of the MedTech practice at Broadview and Managing Director of affiliated fund Longview Ventures, where she was involved in investment strategy, portfolio management, team building and firm operations. The release says she has invested in nearly 20 medtech companies, including several she helped launch, and cites exits such as Apama Medical and CardiAQ. Before Broadview, she was a management consultant at Monitor Group and trained clinically within the Mass General Brigham system at Newton Wellesley Hospital. She holds an MD from the UCLA School of Medicine and an MBA from the UCLA Anderson School of Management.
Segan brings more than 25 years of global medtech experience as a thought leader and physician executive. He previously served as Director of the Office of Product Evaluation and Quality at the FDA's Center for Devices and Radiological Health. His industry roles include Chief Medical Officer of Olympus, Chief Medical Officer of Johnson & Johnson Medical Devices, and medical and clinical affairs leadership at Covidien. The release also notes his U.S. Army Medical Corps service as Chief of Minimally Invasive Surgery, for which he received the Meritorious Service Medal for wartime service during Operation Enduring Freedom. He holds an MD from Rutgers Robert Wood Medical School and an MBA from NYU Stern School of Business.
Managing Partner Justin Klein, MD, JD, described Berkman as an experienced investor and trusted advisor to portfolio companies, while fellow Managing Partner Kirk Nielsen said the firm has known her for many years. Klein characterized Segan as an experienced clinician and medtech executive with deep industry relationships. Nielsen said the additions advance the firm's goal, set when it launched in 2019, of building the deepest and most experienced team in its sector. Vensana's investment team has backed companies including CVRx, Inari Medical, Relievant Medsystems and Vertiflex, according to the release.
Berkman joins Vensana after more than a decade at Broadview Ventures, a firm focused on early-stage investments in cardiovascular disease and stroke. She was most recently Director and Head of the MedTech practice at Broadview and Managing Director of affiliated fund Longview Ventures, where she was involved in investment strategy, portfolio management, team building and firm operations. The release says she has invested in nearly 20 medtech companies, including several she helped launch, and cites exits such as Apama Medical and CardiAQ. Before Broadview, she was a management consultant at Monitor Group and trained clinically within the Mass General Brigham system at Newton Wellesley Hospital. She holds an MD from the UCLA School of Medicine and an MBA from the UCLA Anderson School of Management.
Segan brings more than 25 years of global medtech experience as a thought leader and physician executive. He previously served as Director of the Office of Product Evaluation and Quality at the FDA's Center for Devices and Radiological Health. His industry roles include Chief Medical Officer of Olympus, Chief Medical Officer of Johnson & Johnson Medical Devices, and medical and clinical affairs leadership at Covidien. The release also notes his U.S. Army Medical Corps service as Chief of Minimally Invasive Surgery, for which he received the Meritorious Service Medal for wartime service during Operation Enduring Freedom. He holds an MD from Rutgers Robert Wood Medical School and an MBA from NYU Stern School of Business.
Managing Partner Justin Klein, MD, JD, described Berkman as an experienced investor and trusted advisor to portfolio companies, while fellow Managing Partner Kirk Nielsen said the firm has known her for many years. Klein characterized Segan as an experienced clinician and medtech executive with deep industry relationships. Nielsen said the additions advance the firm's goal, set when it launched in 2019, of building the deepest and most experienced team in its sector. Vensana's investment team has backed companies including CVRx, Inari Medical, Relievant Medsystems and Vertiflex, according to the release.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.